|1.||Williams, Kenneth M: 6 articles (12/2015 - 09/2010)|
|2.||Day, Richard O: 6 articles (12/2015 - 09/2010)|
|3.||Graham, Garry G: 5 articles (12/2015 - 05/2011)|
|4.||Stocker, Sophie L: 4 articles (12/2015 - 09/2010)|
|5.||Springer, Jochen: 3 articles (06/2015 - 11/2012)|
|6.||Doehner, Wolfram: 3 articles (06/2015 - 11/2012)|
|7.||von Haehling, Stephan: 3 articles (06/2015 - 11/2012)|
|8.||Anker, Stefan D: 3 articles (06/2015 - 11/2012)|
|9.||Tschirner, Anika: 3 articles (06/2015 - 11/2012)|
|10.||Stamp, Lisa K: 3 articles (11/2014 - 07/2013)|
|1.||Renal Insufficiency (Renal Failure)
10/31/1986 - "Monitoring of plasma oxipurinol levels (ideally less than 100 mumol/l) by high-pressure liquid chromatography is helpful for adjusting dosage in renal failure. "
12/01/2015 - "Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin."
12/01/1996 - "In some of the patients with renal insufficiency (CCr < 30 ml/min), daily administration of 100 mg of allopurinol resulted in a serum concentration of oxipurinol over 15.2 micrograms/ml. 3. For patients with renal insufficiency (CCr < 30 ml/min), administration of allopurinol at the dosage of 50 mg/day is considered adequate to avoid the accumulation of serum oxipurinol."
12/01/1996 - "In renal insufficiency, the drug must be used cautiously and in reduced dosage because increased serum concentration of oxipurinol, active metabolite of allopurinol, may induce severe side effect."
10/01/1986 - "Allopurinol toxicity has been associated with the use of this drug in patients with renal insufficiency, a situation where the half-life of oxipurinol, the major metabolite of allopurinol, is prolonged. "
10/25/2009 - "These results indicate that the beneficial effects of antioxidation can be sustained by long-term treatment with oxypurinol after ischemic heart failure, with significantly improved cardiac contractility."
06/23/2009 - "The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) trial: a question of dose."
11/01/2004 - "Together these findings form the rationale for the Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients with New York Heart Association (NYHA) class III - IV Congestive Heart Failure (OPT-CHF) trial (Food and Drug Administration IND 65,125), a Phase II - III prospective, randomised, double-blind, placebo-controlled trial, which will include patients with stable symptomatic HF in NYHA class III - IV congestive HF who are deemed clinically stable on a standard and appropriately maximised heart failure therapy regimen. "
11/01/2004 - "Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III - IV congestive heart failure."
10/25/2009 - "Preservation of cardiac contractility after long-term therapy with oxypurinol in post-ischemic heart failure in mice."
01/01/1993 - "In animals given oxypurinol at 5 mg/kg BW 40 min after ischemia, the CIn was significantly greater than in those receiving buffered saline. "
11/19/1993 - "The results of this study are consistent with earlier evidence of free radical formation during ischemia/reperfusion and suggest that the cerebroprotective actions of oxypurinol may be related to its ability to prevent the cascade of free radical generation."
05/01/1995 - "Oxypurinol administration resulted in a significant increase in the energy charge both during ischemia and after 5 min of reperfusion. "
12/01/1989 - "Oxypurinol attenuates ischemia-induced hippocampal damage in the gerbil."
01/01/1988 - "We conclude that oxypurinol administered following 30 min of total ischemia at the onset of reperfusion, can preserve myocardial function during the early reperfusion period in the isolated rat heart."
|4.||Brain Injuries (Brain Injury)
02/15/2003 - "Oxypurinol administration fails to prevent hypoxic-ischemic brain injury in neonatal rats."
05/27/1991 - "Oxypurinol reduces focal ischemic brain injury in the rat."
01/01/1991 - "Oxypurinol reduces ischemic brain injury in the gerbil and rat."
02/07/1992 - "Deoxycoformycin and oxypurinol: protection against focal ischemic brain injury in the rat."
07/01/2009 - "In fetuses/newborns with therapeutic allopurinol/oxypurinol concentrations in cord blood, lower plasma levels of the brain injury marker protein S-100B were detected. "
01/01/2012 - "The control group displayed earlier onset of tumor compared to EPA and oxypurinol groups (P<0.001). "
01/01/2012 - "In combination with EPA, there was little significant improvement from control, indicating oxypurinol is unlikely to be a viable treatment compound in cancer cachexia."
10/09/2013 - "Inhibition of XO with oxypurinol has beneficial effects on cardiac mass and function in a rat model of severe cancer cachexia, suggesting that XO might be a viable drug target in cancer cachexia."
01/01/2012 - "The increased rate of weight decline in mice treated with oxypurinol indicates that XO may play a protective role during the progression of cancer cachexia, and its inhibition is detrimental to outcomes. "
01/01/2012 - "Mice with cancer cachexia were randomized into 4 treatment groups (EPA (0.4 g/kg/day), oxypurinol (1 mmol/L ad-lib), combination, or control), and euthanized after 29 days. "
|3.||Uric Acid (Urate)
|6.||Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)
|1.||Transplantation (Transplant Recipients)